Sven H Loosen, Fabian Benz, Raphael Mohr, Philipp A Reuken, Theresa H Wirtz, Lioba Junker, Christian Jansen, Carsten Meyer, Michael Praktiknjo, Alexander Wree, Johanna Reißing, Münevver Demir, Wenyi Gu, Mihael Vucur, Robert Schierwagen, Andreas Stallmach, Anselm Kunstein, Johannes Bode, Christian Trautwein, Frank Tacke, Tom Luedde, Tony Bruns, Jonel Trebicka, Christoph Roderburg
BACKGROUND & AIMS: Transjugular intrahepatic portosystemic shunt (TIPS) is the most effective therapy for complications of portal hypertension. However, clinical outcomes following TIPS placement vary widely between patients and identifying ideal candidates remains a challenge. Soluble urokinase plasminogen activator receptor (suPAR) is a circulating marker of immune activation that has previously been associated with liver inflammation, but its prognostic value in patients receiving TIPS is unknown...
May 2024: JHEP reports: innovation in hepatology